Premium
Clinical and SD‐OCT pattern of retinal venous occlusion with cystoid macular oedema treated with Ozurdex®
Author(s) -
FORTOUL V,
DENIS P,
KODJIKIAN L
Publication year - 2012
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2012.4614.x
Subject(s) - medicine , macular edema , ophthalmology , retinal vein , visual acuity , implant , dexamethasone , intraocular pressure , fundus (uterus) , fundus photography , central retinal vein occlusion , fluorescein angiography , surgery
Purpose To report our experience with sustained‐release dexamethasone 0.7 mg intravitreal implants (Ozurdex®; Allergan, Inc., Irvine, CA) in first‐line treatment of retinal vein occlusion with macular edema. Methods 26 patients with a minimum follow‐up time of 6 months (CRVO n=15, BRVO n=11) make up our study. Complete ophthalmic examination including visual acuity, fundus biomicroscopy, fundus photography, fluorescein angiography and spectral domain optical coherence tomography (Cirrus SD‐OCT ; Carl Zeiss Meditec, CA) was performed at baseline and follow‐up (1 week, 1 month, 2 months, 3 months, 4 months, 5 months and 6 months) and tolerance of the implant was assessed. Results Twenty‐six eyes of 26 consecutive patients treated with a total of 26 sustained‐release dexamethasone 0.7 mg intravitreal implants for macular edema associated with retinal vein occlusion were included. Thirty‐three percent of patients gained at least 3 lines of best‐corrected visual acuity (BCVA) at 2 months. Forty‐four percent of eyes showed SD‐OCT significative decrease of the edema following implant placement at 1 week (p<0.05). Despite an increase of the macular edema in 57% of the eyes at 4 months, the final best‐corrected visual acuity (BCVA) was still better at 6 months than BCVA at baseline. High intraocular pressure (IOP) was mostly controlled with only one medication after OZURDEX. The peak of IOP was noted in 26% of the eyes at 2 months. Conclusion Sustained‐release dexamethasone 0.7 mg intravitreal implant may be an effective treatment option to control macular edema in patients with retinal vein occlusion. Anatomical and functional benefits of OZURDEX are better when the treatment is done at an early stage.